Literature DB >> 26435256

DNA Topoisomerases.

Natassja G Bush, Katherine Evans-Roberts, Anthony Maxwell.   

Abstract

DNA topoisomerases are enzymes that control the topology of DNA in all cells. There are two types, I and II, classified according to whether they make transient single- or double-stranded breaks in DNA. Their reactions generally involve the passage of a single- or double-strand segment of DNA through this transient break, stabilized by DNA-protein covalent bonds. All topoisomerases can relax DNA, but DNA gyrase, present in all bacteria, can also introduce supercoils into DNA. Because of their essentiality in all cells and the fact that their reactions proceed via DNA breaks, topoisomerases have become important drug targets; the bacterial enzymes are key targets for antibacterial agents. This article discusses the structure and mechanism of topoisomerases and their roles in the bacterial cell. Targeting of the bacterial topoisomerases by inhibitors, including antibiotics in clinical use, is also discussed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26435256     DOI: 10.1128/ecosalplus.ESP-0010-2014

Source DB:  PubMed          Journal:  EcoSal Plus        ISSN: 2324-6200


  58 in total

1.  Trapped topoisomerase II initiates formation of de novo duplications via the nonhomologous end-joining pathway in yeast.

Authors:  Nicole Stantial; Anna Rogojina; Matthew Gilbertson; Yilun Sun; Hannah Miles; Samantha Shaltz; James Berger; Karin C Nitiss; Sue Jinks-Robertson; John L Nitiss
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-12       Impact factor: 11.205

2.  Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase.

Authors:  Elizabeth G Gibson; Ben Bax; Pan F Chan; Neil Osheroff
Journal:  ACS Infect Dis       Date:  2019-02-28       Impact factor: 5.084

Review 3.  Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer.

Authors:  Sonu S Varghese; Cameron R Eekhoudt; Davinder S Jassal
Journal:  Mol Cell Biochem       Date:  2021-04-09       Impact factor: 3.396

4.  Topoisomerase VI is a chirally-selective, preferential DNA decatenase.

Authors:  Shannon J McKie; Parth Rakesh Desai; Yeonee Seol; Adam Mb Allen; Anthony Maxwell; Keir C Neuman
Journal:  Elife       Date:  2022-01-25       Impact factor: 8.140

5.  Antimicrobial Resistance in Clinical Ureaplasma spp. and Mycoplasma hominis and Structural Mechanisms Underlying Quinolone Resistance.

Authors:  Ting Yang; Lianlian Pan; Ningning Wu; Lin Wang; Zhen Liu; Yingying Kong; Zhi Ruan; Xinyou Xie; Jun Zhang
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

6.  Mechanism of Action of Mycobacterium tuberculosis Gyrase Inhibitors: A Novel Class of Gyrase Poisons.

Authors:  Elizabeth G Gibson; Tim R Blower; Monica Cacho; Ben Bax; James M Berger; Neil Osheroff
Journal:  ACS Infect Dis       Date:  2018-05-17       Impact factor: 5.084

7.  DNA supercoiling-mediated collective behavior of co-transcribing RNA polymerases.

Authors:  Shubham Tripathi; Sumitabha Brahmachari; José N Onuchic; Herbert Levine
Journal:  Nucleic Acids Res       Date:  2022-02-22       Impact factor: 16.971

8.  The pentapeptide-repeat protein, MfpA, interacts with mycobacterial DNA gyrase as a DNA T-segment mimic.

Authors:  Lipeng Feng; Julia E A Mundy; Clare E M Stevenson; Lesley A Mitchenall; David M Lawson; Kaixia Mi; Anthony Maxwell
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-16       Impact factor: 11.205

9.  Topoisomerase I Essentiality, DnaA-Independent Chromosomal Replication, and Transcription-Replication Conflict in Escherichia coli.

Authors:  J Krishna Leela; Nalini Raghunathan; J Gowrishankar
Journal:  J Bacteriol       Date:  2021-08-09       Impact factor: 3.490

10.  Implications of Topoisomerase (TOP1 and TOP2α) Expression in Patients With Breast Cancer.

Authors:  Misato Ogino; Takaaki Fujii; Yuko Nakazawa; Toru Higuchi; Yukio Koibuchi; Tetsunari Oyama; Jun Horiguchi; Ken Shirabe
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.